{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T16:28:04Z","timestamp":1772382484374,"version":"3.50.1"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/mol.0b013e3283613a3d","type":"journal-article","created":{"date-parts":[[2013,5,7]],"date-time":"2013-05-07T08:43:33Z","timestamp":1367916213000},"page":"251-258","source":"Crossref","is-referenced-by-count":40,"title":["PCSK9 inhibitors"],"prefix":"10.1097","volume":"24","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20211004","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-12-20211004","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases.","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R3-12-20211004","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"R4-12-20211004","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France.","volume":"31","author":"Marduel","year":"2010","journal-title":"Human Mut"},{"key":"R5-12-20211004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"R6-12-20211004","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-12-20211004","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses.","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R8-12-20211004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/11590330-000000000-00000","article-title":"The role of proprotein convertase subtilisinkexin type 9 in hyperlipidemia. Focus on therapeutic implications.","volume":"11","author":"Farnier","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"R9-12-20211004","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisinkexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R10-12-20211004","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade.","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"R11-12-20211004","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/clp.12.74","article-title":"PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials.","volume":"7","author":"Rhainds","year":"2012","journal-title":"Clin Lipid"},{"key":"R12-12-20211004","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9LDLR structure at neutral pH.","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep"},{"key":"R13-12-20211004","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins.","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"R14-12-20211004","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisinkexin type 9.","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"R15-12-20211004","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"R16-12-20211004","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersentivity to statins in mice lacking PCSK9.","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R17-12-20211004","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of PCSK9 reduces atherosclerosis in mice.","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"R18-12-20211004","first-page":"938","article-title":"Targeting PCSK9 for the treatment of hypercholesterolemia.","volume":"10","author":"Hedrick","year":"2009","journal-title":"Curr Opin Invest Drugs"},{"key":"R19-12-20211004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1517\/14728220802600715","article-title":"PCSK9 as a therapeutic target of dyslipidemia.","volume":"13","author":"Seidah","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"R20-12-20211004","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1517\/13543776.2010.518615","article-title":"Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.","volume":"20","author":"Abifadel","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"R21-12-20211004","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14728222.2011.547480","article-title":"PCSK9: an emerging target for treatment of hypercholesterolemia.","volume":"15","author":"Duff","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"R22-12-20211004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/MOL.0b013e3283587563","article-title":"Proprotein convertase subtilisinkexin type 9 inhibition.","volume":"23","author":"Marais","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"R23-12-20211004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisinkexin type 9 reduces serum LDL in hyperlipidemic mice.","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"R24-12-20211004","doi-asserted-by":"crossref","first-page":"e10682","DOI":"10.1371\/journal.pone.0010682","article-title":"A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.","volume":"5","author":"Gupta","year":"2010","journal-title":"PLoS One"},{"key":"R25-12-20211004","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/mt.2011.260","article-title":"PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.","volume":"20","author":"Lindholm","year":"2012","journal-title":"Mol Ther"},{"key":"R26-12-20211004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14712598.2012.748743","article-title":"Anti-PCSK9 therapies for the treatment of hypercholesterolemia.","volume":"13","author":"Hooper","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"R27-12-20211004","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates.","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R28-12-20211004","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1194\/jlr.M013664","article-title":"Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9.","volume":"52","author":"Ason","year":"2011","journal-title":"J Lipid Res"},{"key":"R29-12-20211004","doi-asserted-by":"crossref","first-page":"A67","DOI":"10.1161\/atvb.32.suppl_1.A67","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamics results for ALN-PCS, a novel RNAi therapeutic for the treatment of hypercholesterolemia.","volume":"32","author":"Fitzgerald","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R30-12-20211004","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin Chem"},{"key":"R31-12-20211004","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisinkexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"R32-12-20211004","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1194\/jlr.M011445","article-title":"A PCSK9-binding antibody that structurally mimics the EFG(A) domain of LDL-receptor reduces LDL cholesterol in vivo.","volume":"52","author":"Ni","year":"2011","journal-title":"J Lipid Res"},{"key":"R33-12-20211004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.187419","article-title":"Proprotein convertase subtilisinkexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.","volume":"340","author":"Liang","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"R34-12-20211004","doi-asserted-by":"crossref","first-page":"12882","DOI":"10.1074\/jbc.M110.113035","article-title":"A proprotein convertase subtilisin-likekexin type 9(PCSK9) C-terminal domain antibody antigene-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.","volume":"285","author":"Ni","year":"2010","journal-title":"J Biol Chem"},{"key":"R35-12-20211004","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"R36-12-20211004","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisinkexin type 9 serine protease, SAR236553REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R37-12-20211004","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"R38-12-20211004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","article-title":"Effect of a monoclonal antibody to PCSK9, REG727SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"R39-12-20211004","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"for the LAPLACE-TIMI 57 investigatorsEfficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisinkexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"R40-12-20211004","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisinkexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial.","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"R41-12-20211004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisinkexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"R42-12-20211004","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. The GAUSS randomized trial.","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"R43-12-20211004","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels.","volume":"60","author":"Dias","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R44-12-20211004","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.1074\/jbc.M111.319764","article-title":"Increasing serum half-life and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9.","volume":"287","author":"Chaparro-Riggers","year":"2012","journal-title":"J Biol Chem"},{"key":"R45-12-20211004","first-page":"A13322","article-title":"The effects of single dose administration of RN316 (PF-04950615), a humanized IgG2a monoclonal antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin.","volume":"126","author":"Gumbiner","year":"2012","journal-title":"Circulation"},{"key":"R46-12-20211004","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"R47-12-20211004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.","volume":"193","author":"Hopper","year":"2007","journal-title":"Atherosclerosis"},{"key":"R48-12-20211004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","article-title":"Circulating proprotein convertase subtilisinkexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.","volume":"31","author":"Roubtsova","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R49-12-20211004","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.febslet.2009.12.018","article-title":"PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.","volume":"584","author":"Mbikay","year":"2010","journal-title":"FEBS Lett"},{"key":"R50-12-20211004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ahj.2004.03.052","article-title":"Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.","volume":"148","author":"Stein","year":"2004","journal-title":"Am Heart J"},{"key":"R51-12-20211004","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T07:00:47Z","timestamp":1715324447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e3283613a3d","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}